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INTRODUCTION
Multiple myeloma (MM) is a plasma cell malignancy with high osteolytic capacity and impaired bone formation. The receptor activator of NFkB ligand (RANKL) signaling pathway plays a critical role in normal bone remodeling and myeloma bone disease. In myeloma, RANKL expression is markedly increased while osteoprotegerin (OPG), its decoy receptor for RANKL, is decreased (1, 2) . In addition, the Wnt signaling pathway has also been associated with the characteristic osteoblastic dysfunction in myeloma. Supporting this idea, the expression of the Wnt signaling inhibitor, DKK1, is significantly increased in patients with myeloma and correlates with the extent of bone disease (3, 4) . The ubiquitin-proteasome pathway which is an essential cellular degradative system in myeloma cells can also regulate bone formation via effects on osteoblast differentiation (5, 6) . The proteasome inhibitor, bortezomib, has been shown to inhibit myeloma progression in the myeloma SCID-hu model in vivo. In these studies, bortezomib treatment (0.5 mg/kg twice a week) of myeloma-bearing scid-mice was associated with an increase in bone mineral density (BMD) (20%+/-14%), while in untreated animals, myeloma growth induce a decrease in BMD (13%+/-12%). Exposure of non-myeloma-bearing control mice to bortezomib also resulted in a significant increase in BMD (7).
Retrospective analysis of the variation of bone alkaline phosphatase (bALP) during bortezomib treatment has indicated a close correlation between myeloma response and drug activity (8) . In the study described here, we report the first prospective study of bortezomib-associated bone and hormonal changes. Under general anesthesia bone biopsy specimens of ~7 mm in diameter which included the two cortices and the intervening cancellous bone were obtained for histomorphometric evaluation. Samples were fixed in iced Millonig's phosphatebuffered 10% formalin at pH 7.4.
Prior to histological preparation of the biopsy, all specimens were examined by high-resolution micro-computed tomography (micro-CT) using a µCT40 system (Scanco Medical, Bassersdorf, Switzerland) with a spatial resolution of 28 µm.
The harvested bone biopsy samples were immediately scanned in Millonig's phosphate-buffered 10% formalin at pH 7.4. Within 24 hours, the samples were dehydrated in graded ethanol solutions before being embedded undecalcified in methylmethacrylate (10).
Microarchitectural Micro-CT data were acquired by scanning at 55 keV and 145 mA, with a field of vision of 36.8 mm and a matrix of 1024 x 1024 x 808 with an isotropic voxel size. For each analysis, an average of 100 contiguous slices were contoured by user-defined thresholds for trabecular bone and iterated across slices using the Scanco software to derive measures of architectural parameters. The histomorphometric examination of the samples were performed with the use of a digitizer tablet (Osteo-Metrics) as described previously (11, 12) using the terminology of Parfitt (12) . The cancellous bone measurements were twodimensional and made at a magnification of 20X. Routine bone marrow for histology and cytogenetic analysis was also obtained at baseline from all patients and at the end of the study period.
All patients enrolled in this analysis signed an informed consent approved by the Institutional Review Board.
RESULTS
A total of 16 patients, 10 on the first cohort and 6 on the second cohort were enrolled in the study; with a median age of 62 years; seven were male. All enrolled patients had relapsing or refractory disease, 75% after being exposed to autologous bone marrow transplant and with a median time from diagnosis of 48 months. Seven of the sixteen evaluable patients achieved at least PR during treatment.
The median osteocalcin value increased from 1.95 mg/ml at baseline to 7.16 mg/ml at the end of study. bALP ranged from 4.5 to 48.4 mg/ml at baseline and was significantly increased during treatment in responsive patients following bortezomib exposure (p=0.03 on day 12, cycle 1). No significant serum variations from baseline of calcium, magnesium and phosphorus were recorded during Bortezomib treatment.
Micro CT measurements were obtained in 11 patients at baseline and in 9
patients at the end of study; two samples were felt to be inadequate and 7 patients were evaluable for comparative paired evaluation. Architectural parameters such as bone volume/total volume (BV/TV), trabecular number (TbN) and trabecular thickness (TbTh) were determined ( Table 1 ). The measurements of BV/TV ranged from 13% to 90% at baseline and after bortezomib exposure a significant increase in BV/TV was measured in 6 of 7 patients (p<0.02).
Interestingly, trabecular thickness also increased from baseline (range 20% -45.6%) in 5 of the 7 patients who responded to bortezomib. A 3-dimensional micro-CT rendering from a responding and a non-responding patient is shown DOI: 10.3324/haematol.2010.031302
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( Figure 1A ). The BV/TV increased from 12% at baseline to 90% after 12 doses of bortezomib in the responding patient.
Histologically, a lack of osteoid formation and osteoblast activity was consistently observed at baseline with an increase in both osteoid and osteoblast number after bortezomib treatment observed only in responsive patients. Similarly, bortezomib induced increases in osteoblast activity as observed by increased osteoid, osteoblast number and the appearance of labeled bone surfaces ( Figure   1B ).
In addition, the measurement of dynamic histomorphometric indices was also performed by the evaluation of tetracycline-labeled bone surfaces.
At baseline only 2 of the 11 patients samples (18%) showed evidence of tetracycline labeling of bone under polarized microscopy. However, after 12 doses of bortezomib, evidence of tetracycline incorporation (single labeled surface) was observed in 7 (63%) biopsy samples (p<0.03 baseline vs. posttreatment score changes). Moreover, the 2 patients with evidence of baseline tetracycline labeling, after bortezomib exposure showed significantly increased double labeled surfaces.
Serial PTH samples were collected in all enrolled patients. Median PTH variation across cycle of the entire group and by myeloma response is shown (Figure 2 ).
Comparing patients who achieved at least a PR versus the others, median PTH levels separate after the second bortezomib dose and were statistically higher in responding patients on days 11 (p=0.04), 21 (p=0.04), and 33 (p=0.04) ( Figure   2 ). Comparing the PTH concentration measured over the dosing interval in 9 responders versus non-responders showed a significant difference in the average concentration over the first cycle (Av +/-SD for R = 85.6 +/-16.9
NR=54.4+/-7.1, P<0.001). The change in PTH from baseline was not different in control patients.
DISCUSSION
In the SUMMIT and APEX trials we previously described a statistically significant elevation of ALP in bortezomib responding patients. Since bortezomib exposure had little or no effect on DKK1 or FOSB RNA expression in purified myeloma cells (our unpublished data) the results obtained from whole bone biopsy suggest that bortezomib acts via the microenvironment, as suggested by preclinical studies demonstrating that bortezomib inhibits RANK-L induced osteoclastogenesis (18) . Interestingly, the significant bone anabolism following bortezomib treatment was preceded only in responsive patients by a significant pulsatile increase in serum PTH levels without concomitant significant changes in Ca, Mg, or phosphorus levels.
The rapid increases in serum PTH levels following daily administration of the hormone (19, 20, 21) 
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